BGB-11417 在患有成熟 B 细胞恶性肿瘤的成人参与者中的研究
评估 Bcl-2 抑制剂 BGB-11417 在成年 B 细胞恶性肿瘤患者中的安全性、耐受性、药代动力学和初步抗肿瘤活性的 1 期研究
The purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy for the selected B-cell malignancy dose finding cohorts, and evaluate the safety and tolerability of the ramp-up dosing schedule in the evaluated disease types.
研究概览
详细说明
This study will have 3 cohorts for determining a monotherapy MTD and ramp-up schedule: Cohort A, participants with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R NHL); Cohort B, participants with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with low tumor burden; Cohort C, participants with R/R CLL/SLL with high tumor burden.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100034
- Peking University First Hospital
-
Beijing、Beijing Municipality、中国、100044
- Peking University Peoples Hospital
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- Sun Yat Sen University Cancer Center
-
Shenzhen、Guangdong、中国、518020
- Shenzhen Peoples Hospital
-
-
Henan
-
Zhengzhou、Henan、中国、450000
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan、Hubei、中国、430030
- Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
-
-
Hunan
-
Changsha、Hunan、中国、410013
- Hunan Cancer Hospital
-
-
Jiangsu
-
Suzhou、Jiangsu、中国、215006
- The First Affiliated Hospital of Soochow University
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- The First Affiliated Hospital of Nanchang University Branch Donghu
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- Affiliated Zhongshan Hospital of Fudan University
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310003
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
Confirmed diagnosis of only one of the following:
Cohort A
a. Marginal Zone Lymphoma
i. R/R extranodal, splenic or nodal disease defined as disease that has relapsed after, or been refractory to, ≥ 1 line of anti-CD20 antibody-based chemoimmunotherapy for ≥ 2 consecutive cycles, and no effective standard therapy for MZL is available per investigator's assessment.
ii. Active disease requiring treatment.
b. Follicular Lymphoma
i. R/R FL (Grade 1, 2 or 3a based on the WHO 2008 classification of tumors of hematopoietic and lymphoid tissue) and defined as disease that has relapsed after, or been refractory to, ≥ 1 line of anti-CD20 antibody-based chemoimmunotherapy for ≥ 2 consecutive cycles, and no effective standard therapy for FL is available per investigator's assessment.
ii. Active disease requiring treatment.
c. Diffuse Large B-cell Lymphoma
i. R/R DLBCL defined as disease that relapsed after, or been refractory to, at least one line of anti-CD20 antibody based chemoimmunotherapy for ≥ 2 consecutive cycles, and no effective standard therapy for DLBCL is available per investigator's assessment.
ii. Active disease requiring treatment.
d. Transformed indolent B-cell NHL
i. Any lymphoma otherwise eligible for Cohort A that has transformed into a more aggressive lymphoma. Patients with transformation from CLL or SLL (Richter's transformation) are not eligible for Cohort A.
ii. Active disease requiring treatment.
Cohorts B and C
a. CLL/SLL diagnosis that meets the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria:
i. R/R disease defined as disease that has relapsed after, or been refractory to, ≥ 1 line of standard therapy for ≥ 2 consecutive cycles, and no effective standard therapy is available per investigator's assessment.
ii. Requiring treatment based on IWCLL criteria.
-
Measurable disease by computed tomography/magnetic resonance imaging, defined as:
- CLL: At least 1 lymph node > 1.5 centimeters (cm) in longest diameter and measurable in 2 perpendicular dimensions. For Cohort B, participants should not meet with the definition of high tumor burden, which is required for participants enrolled in Cohort C.
- DLBCL, FL, MZL, SLL: At least 1 lymph node > 1.5 cm in longest diameter OR 1 extranodal lesion > 1.0 cm in the longest diameter, measurable in 2 perpendicular dimensions. For MZL isolated splenomegaly is considered to indicate measurable disease for this study. For SLL, participants in Cohort B should not meet with the definition of high tumor burden, which is required for participants enrolled in Cohort C.
Key Exclusion Criteria:
- Prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer.
- Underlying medical conditions that, in the investigator's opinion, will render the administration of study drug hazardous or obscure the interpretation of safety or efficacy results.
- Known central nervous system involvement by lymphoma/leukemia.
- Known plasma cell neoplasm, prolymphocytic leukemia, history of or currently suspected Richter's syndrome.
- Prior autologous stem cell transplant unless ≥ 3 months after transplant; or prior chimeric cell therapy unless ≥ 6 months after cell infusion.
- Prior allogeneic stem cell transplant.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort A: R/R NHL
Participants with R/R NHL, including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), or transformed NHL, will receive oral BGB-11417 until the MTD (or maximum ascending dose [MAD]) and the RP2D can be determined. |
Film-coated tablets administered orally as specified in the treatment arm.
其他名称:
|
|
实验性的:Cohort B: R/R CLL/SLL (low tumor burden)
Participants with low tumor burden R/R CLL/SLL will receive oral BGB-11417 until the MTD (or MAD) and the RP2D can be determined. |
Film-coated tablets administered orally as specified in the treatment arm.
其他名称:
|
|
实验性的:Cohort C: R/R CLL/SLL (high tumor burden)
Participants in this cohort will not be enrolled until the RP2D for Cohort B is established. Participants will be treated with the monotherapy ramp-up schedule and the RP2D established in Cohort B. |
Film-coated tablets administered orally as specified in the treatment arm.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
贝叶斯逻辑回归模型或 MAD 推荐的 BGB-11417 的 MTD
大体时间:约3年
|
约3年
|
|
|
肿瘤溶解综合征相关事件的发生率和严重程度
大体时间:约3年
|
约3年
|
|
|
RP2D Of BGB-11417
大体时间:Approximately 3 years
|
The RP2D will be decided by the sponsor and based on the safety monitoring committee recommendation considering totality of data. |
Approximately 3 years
|
|
Incidence And Severity Of Treatment-emergent Adverse Events, Serious Adverse Events, Adverse Events (AEs) Leading To Discontinuation, And Dose-Limiting Toxicities (DLTs)
大体时间:Approximately 3 years
|
All AEs, including DLT events, will be assessed per National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 (or the Grading Scale for Hematologic Toxicity in CLL Studies as appropriate). |
Approximately 3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
通过 BGB-11417 的最大观察血浆浓度 (Cmax) 评估的药代动力学 (PK)
大体时间:给药后长达 24 小时
|
给药后长达 24 小时
|
|
|
从时间 0 到 BGB-11417 的最后可量化浓度 (AUC0-t) 的血浆浓度时间曲线下面积评估的 PK
大体时间:给药后长达 24 小时
|
给药后长达 24 小时
|
|
|
根据 BGB-11417 从时间 0 到无穷大 (AUC0-inf) 的血浆浓度时间曲线下面积评估的 PK
大体时间:给药后长达 24 小时
|
给药后长达 24 小时
|
|
|
根据 BGB-11417 的最大观察血浆浓度 (tmax) 时间评估的 PK
大体时间:给药后长达 24 小时
|
给药后长达 24 小时
|
|
|
通过 BGB-11417 的终末半衰期 (t1/2) 评估的 PK
大体时间:给药后长达 24 小时
|
给药后长达 24 小时
|
|
|
通过口服 BGB-11417 后药物从血浆中的表观总清除率 (CL/F) 评估的 PK
大体时间:给药后长达 24 小时
|
给药后长达 24 小时
|
|
|
通过 BGB-11417 的表观分布容积 (Vz/F) 评估的 PK
大体时间:给药后长达 24 小时
|
给药后长达 24 小时
|
|
|
根据 BGB-11417 的稳态 (AUClast,ss) 从时间 0 到最后可测量浓度的血浆浓度时间曲线下面积评估的 PK
大体时间:给药后长达 24 小时
|
给药后长达 24 小时
|
|
|
通过 BGB-11417 的稳态最大观察血浆浓度 (Cmax,ss) 评估的 PK
大体时间:给药后长达 24 小时
|
给药后长达 24 小时
|
|
|
通过 BGB-11417 的稳态(谷,ss)谷浓度评估的 PK
大体时间:给药后长达 24 小时
|
给药后长达 24 小时
|
|
|
根据 BGB-11417 在稳态 (tmax,ss) 下观察到的最大血浆浓度的时间评估的 PK
大体时间:给药后长达 24 小时
|
给药后长达 24 小时
|
|
|
Overall Response Rate (ORR) Of BGB-11417 Monotherapy
大体时间:Approximately 3 years
|
ORR will be assessed per disease-specific response assessment guidelines as determined by the investigator. |
Approximately 3 years
|
合作者和调查者
赞助
调查人员
- 研究主任:Lu Zhang, M.D.、BeiGene (Suzhou) Co., Ltd.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.